Search PubMedSearch

Biomedical subjects

L Huffman

Publications and source records attributed to L Huffman.

18 recordsLinked to original sources

Constitutive nitric oxide production by rat alveolar macrophages.

Results from previous studies suggest that alveolar macrophages must be exposed to inflammatory stimuli to produce nitric oxide (.NO). In this study, we report that naive unstimulated rat alveolar macrophages do produce .NO and attempt to characterize this process. Western blot analysis demonstrates that the enzyme responsible is an endothelial nitric oxide synthase (eNOS). No brain or inducible NOS can be detected. The rate of .NO production is approximately 0.07 nmol.10(6) cells-1.h-1, an amount that is less than that produced by the eNOS found in alveolar type II or endothelial cells. Alveolar macrophage .NO formation is increased in the presence of extracellular L-arginine, incubation medium containing magnesium and no calcium, a calcium ionophore (A-23187), or methacholine. .NO production is inhibited by NG-nitro-L-arginine methyl ester (L-NAME) but not by NG-nitro-L-arginine, L-N5-(1-iminomethyl)ornithine hydrochloride, or aminoguanidine. Incubation with ATP, ADP, or histamine also inhibits .NO formation. Some of these properties are similar to and some are different from properties of eNOS in other cell types. Cellular .NO levels do not appear to be related to ATP or lactate content. Alveolar macrophage production of .NO can be increased approximately threefold in the presence of lung surfactant or its major component, dipalmitoyl phosphatidylcholine (DPPC). The DPPC-induced increase in .NO formation is time and concentration dependent, can be completely inhibited by L-NAME, and does not appear to be related to the degradation of DPPC by alveolar macrophages. These results demonstrate that unstimulated alveolar macrophages produce .NO via an eNOS and that lung surfactant increases .NO formation. This latter effect may be important in maintaining an anti-inflammatory state in vivo.

Adenosine Triphosphate

Alveolar type II cell cNOS activity and ATP levels are increased by lung surfactant or DPPC vesicles.

In a previous study, we reported that nitric oxide (.NO) affects surfactant synthesis and ATP levels in alveolar type II cells and suggested that there is constitutive nitric oxide synthase (cNOS) activity in the cells. In the present study, we performed experiments to confirm further the presence of cNOS and to determine the effects of lung surfactant on type II cell .NO and ATP levels. The supernatant from freshly isolated cells contains .NO (0.26 +/- 0.08 nmol/10(6) cells). During incubation, the cells produce additional .NO at a rate of approximately 0.3 nmol.10(5) cells-1.h-1. .NO formation is inhibited by 28-46% by three inhibitors of cNOS and inducible NOS (iNOS), NG-monomethyl-L-arginine (L-NMMA), L-N5-(1-iminoethyl)ornithine hydrochloride, and NG-nitro-L-arginine methyl ester, but a specific inhibitor of iNOS, aminoguanidine, has no effect. The production of .NO is reduced in Ca(2+)-free medium, is stimulated by the Ca2+ ionophore A-23187, and is independent of extracellular L-arginine. One known type of cNOS, endothelial NOS (eNOS), can be detected in the cells by using Western blot analysis. Incubation of the cells with lung surfactant leads to a relatively rapid (approximately 15 min), concentration-dependent increase in .NO formation that reaches levels as high as 238 +/- 14% of control. The surfactant effects appear to be caused by its major component, dipalmitoyl phosphatidylcholine (DPPC). Exposure of type II cells to DPPC results in maximal increases in .NO formation, ATP content, and O2 consumption, which are 268 +/- 32, 234 +/- 24, and 131 +/- 6% of control, respectively. The DPPC-induced increases in .NO, ATP, and O2 consumption are inhibited by L-NMMA. These results confirm the presence of type II cell cNOS and suggest that it may have a role in the cellular processing of lung surfactant.

1,2-Dipalmitoylphosphatidylcholine

Epilogue: bridging the gap between research on attachment and psychopathology.

Clinicians and researchers are beginning to acknowledge the importance of integrating a developmental perspective into the understanding of clinical disorders. The application of findings from basic attachment research to this understanding of psychopathology is a prototype for interdisciplinary research. However, major gaps continue to exist between basic research on attachment processes and clinical issues of assessment, classification, and treatment of mental disorders from infancy through adolescence. This epilogue highlights the importance of more integrative research. As a reflection of growth in this direction, National Institute of Mental Health funding patterns are reviewed, and promising areas for future research are suggested. The field is well positioned for conceptual advancement if more integrative approaches are used.

Humans

Nitric oxide alters metabolism in isolated alveolar type II cells.

Alveolar type II cells may be exposed to nitric oxide (.NO) from external sources, and these cells can also generate .NO. Therefore we studied the effects of altering .NO levels on various type II cell metabolic processes. Incubation of cells with the .NO generator, S-nitroso-N-acetylpenicillamine (SNAP; 1 mM), leads to reductions of 60-70% in the synthesis of disaturated phosphatidylcholines (DSPC) and cell ATP levels. Cellular oxygen consumption, an indirect measure of cell ATP synthesis, is also reduced by SNAP. There is no direct effect of SNAP on lung mitochondrial ATP synthesis, suggesting that .NO does not directly inhibit this process. On the other hand, incubation of cells with NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS), the enzyme responsible for .NO synthesis, results in increases in DSPC synthesis, cell ATP content, and cellular oxygen consumption. The L-NAME effects are reversed by addition of L-arginine, the substrate for NOS. Production of .NO by type II cells is inhibited by L-NAME, a better inhibitor of constitutive NOS (cNOS) than inducible NOS (iNOS), and is reduced in the absence of external calcium. Aminoguanidine, a specific inhibitor of iNOS, has no effect on cell ATP content or on .NO production. These results indicate that alveolar type II cell lipid and energy metabolism can be affected by .NO and suggest that there may be cNOS activity in these cells.

Adenosine Triphosphate

NPY is not a primary mediator of the acute thyroid blood flow response to sympathetic nerve stimulation.

It has been suggested that thyroid blood flow is regulated by both sympathetic and parasympathetic nerves. The purpose of our experiments was to study the role of neuropeptide Y (NPY) in the sympathetic neural control of thyroid blood flow. Sympathetic nerve fibers to the thyroid contain both norepinephrine (NE) and NPY. Therefore, NE (15 nmol iv bolus) and NPY (12 or 1.7 nmol/kg body wt iv infusion; 4 min) were administered to anesthetized male rats (250-300 g) either alone or together, with or without an alpha-adrenergic receptor blocker (phentolamine; 10 mg/kg body wt iv bolus). Experiments were also performed in which the cervical sympathetic trunks were stimulated (30 Hz, 10 V; 0.5 ms; 2 min) with or without phentolamine. Thyroid blood flow was monitored continuously by laser-Doppler blood flowmetry. Results are expressed as thyroid vascular conductance (TVC). NE or NPY at both doses decreased TVC relative to that in control saline-infused rats (P < 0.05). No potentiation of the NE effect by NPY was observed when the first dose of NE was injected 2 min after a high or low dose of NPY. However, the effect of a second dose of NE, injected 15 min after the end of the low dose of NPY, was prolonged compared with the effect of a second dose of NE in saline-infused rats. Phentolamine blocked the effect of NE but not that of NPY. Stimulation of the cervical sympathetic trunks decreased TVC (P < 0.01 vs. sham), and this effect was completely blocked by phentolamine.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals

Helodermin, but not cholecystokinin, somatostatin, or thyrotropin releasing hormone, acutely increases thyroid blood flow in the rat.

In the present study, we investigated whether peptides located within the thyroid gland, but not directly found in nerve fibers associated with blood vessels, might influence thyroid blood flow. Specifically, we evaluated the effects of helodermin, cholecystokinin (CCK), somatostatin (SRIF) and thyrotropin releasing hormone (TRH) given systemically on thyroid blood flow and circulating thyroid hormone levels. Blood flows in the thyroid and six other organs were measured in male rats using 141Ce-labeled microspheres. Circulating thyrotropin (TSH) and thyroid hormone levels were monitored by RIA. Helodermin (10(-10) mol/100 g BW, i.v. over 4 min) markedly elevated thyroid blood flow (52 +/- 6 vs. 10 +/- 2 ml/min.g in vehicle-infused rats; n = 5). Blood flows to the salivary gland, pancreas, lacrimal gland and stomach (but not adrenal and kidney) were also increased during helodermin infusions. CCK, SRIF, and TRH were without effect on blood flows to the thyroid and other organs even though these peptides were tested at higher molar doses than helodermin. Helodermin, CCK, or SRIF did not affect thyroid hormone or plasma calcium levels. As expected however, plasma TSH and T3 levels were increased at 20 min and 2 h, respectively, following TRH infusions. Since helodermin shares sequence homology with VIP, we next compared the relative effects of these two peptides on thyroid and other organ blood flows. VIP (10(-11) mol/100 g BW, i.v.) was more potent in increasing blood flows to the thyroid, salivary gland, and pancreas than an equimolar dose of helodermin. This study shows that while helodermin, like VIP, has the ability to increase thyroid and other organ blood flows, it appears to be a less potent vasodilator.

Animals

Early development of the thyroid axis in the Brattleboro rat.

Plasma concentrations of thyrotrophin (TSH), thyroxine (T4), and triiodothyronine (T3), and pituitary TSH concentrations were determined at weekly intervals during the first 42 days following birth in Brattleboro homozygous (DI), Brattleboro heterozygous (HZ), and Long-Evans (LE) rats. Offspring from matings of Brattleboro rats were divided into DI and HZ animal subgroups on the basis of hypothalamic vasopressin content. In control LE rats, circulating levels of TSH, T4, and T3, and pituitary TSH concentrations increased during the early postnatal period to reach relatively stable levels between 28 and 42 days of age. In DI and HZ rats, the thyroid axis developed in parallel to that of LE rats during initial postnatal weeks. However, by 42 days of age, pituitary TSH concentrations were clearly elevated in Brattleboro rats relative to levels in age-matched LE animals. These data indicate that differences in thyroid axis function between Brattleboro and LE rats occur only after the attainment of a degree of maturity.

Animals

Neuropeptide control of thyroid blood flow and hormone secretion in the rat.

The effects of peptide HI (PHI), neuropeptide Y (NPY), and substance P (SP) on thyroid blood flow and hormone levels were studied in anesthetized rats. Regional blood flows were determined using radioactive microspheres. No change in heart rate or mean left ventricular pressure occurred during these neuropeptide infusions (0.625 micrograms iv over 2 min). PHI treatment resulted in a four-fold increase in thyroid blood flow. Blood flows to the pancreas and salivary gland also increased during PHI treatment. Infusions of NPY or SP did not significantly alter thyroid blood flow. However, SP decreased blood flow to the spleen and small intestine. These neuropeptides had no effect on blood flows to the adrenal, kidney, brain, heart, and adipose tissues. Following PHI, NPY, and SP infusions, plasma triiodothyronine and thyroxine levels were not different from values in saline-treated rats. This study demonstrates that PHI, like vasoactive intestinal peptide, is a potent thyroidal vasodilator at a dose that does not affect circulating thyroid hormone secretion.

Animals

Effects of vasoactive intestinal peptide on thyroid blood flow and circulating thyroid hormone levels in the rat.

The effects of vasoactive intestinal peptide (VIP) on thyroid blood flow and hormone levels were studied in rats. Tissue blood flow was determined from the distribution of radioactive microspheres after injection by cardiac puncture directly into the left ventricle of anesthetized rats. Initial results indicated that the systemic infusion of 6.25 micrograms VIP iv resulted in increased thyroid blood flow, but was also associated with hypotension, as measured by left ventricular pressure. In contrast, topical administration of VIP to the left of the thyroid increased blood flow to that lobe, but not to the right lobe, and produced no systemic cardiovascular effects. In a further set of experiments, graded doses of VIP were administered iv. Infusions of 6.25 and 0.625 micrograms VIP were associated with 2- to 3-fold increases in thyroid and pancreatic blood flows, but lower doses were ineffective. Blood flows to the adrenals, brain, small intestine, kidneys, and spleen were not altered by any dose of VIP. Mean left ventricular pressure was again reduced by the 6.25-micrograms dose of VIP, but was not affected by lower doses. The infusions of VIP had no effect on plasma TSH, T3, or T4 levels either 20 min or 2 h after treatment. These results suggest that thyroid blood flow is, in part, controlled by VIP and indicate that changes in thyroid blood flow can occur at doses of VIP that have no apparent effect on circulating thyroid hormone levels.

Animals

Carotid sinus baroreceptor activity in the nonhuman primate.

The carotid sinus of eight adult Macaca fascicularis monkeys was functionally isolated from the circulation and perfused with Krebs-Henseleit solution. The impulse activity in 65 carotid sinus baroreceptor fibers from the left carotid sinus nerve was studied during nonpulsatile perfusion and was compared with the impulse activity in 68 fibers from 10 adult mongrel dogs. Curves relating the discharge frequency to carotid sinus pressure were constructed. The baroreceptor fibers of the monkey had a significantly lower threshold, gain, pressure at the point of inflection, and plateau pressure than those of the dog. Hysteresis, as indicated by the separation of the stimulus-response curves obtained by increasing and then decreasing carotid sinus pressure, was observed. At any given pressure, the discharge frequency of baroreceptors was greater when carotid sinus pressure was increased than when it was decreased in both species. These results provide direct evidence that carotid sinus baroreceptors in the monkey are less sensitive to pressure changes than those in the dog.

Animals

Arginine vasotocin and renal function in the conscious dog.

The effects of arginine vasotocin (AVT), 4-6 ng/kg, on renal function and plasma prolactin (PRL) were determined in conscious American foxhounds undergoing a water diuresis. Intravenous AVT produced an antidiuresis, kaliuresis and inconsistent natriuresis, independently of changes in GFR, blood pressure, heart rate and plasma PRL.

Animals

Sympathetic thyroidal vasoconstriction is not blocked by a neuropeptide Y antagonist or antiserum.

Sympathetic nerve fibers to thyroid blood vessels contain both norepinephrine (NE) and neuropeptide Y (NPY). To assess the involvement of endogenous NPY in the sympathetic neural control of thyroid blood flow, appropriate doses of a selective NPY antagonist, alpha-trinositol, and an NPY antiserum (NPY-AS) were used during cervical sympathetic trunk stimulation in anesthetized rats. During all experiments, thyroid blood flow was continuously monitored by laser Doppler blood flowmetry. Neither alpha-trinositol nor NPY-AS blocked the thyroidal vasoconstriction evoked by either the first or second stimulation of the cervical sympathetic trunks. Our results suggest that NPY is not involved either directly or indirectly during acute sympathetic vasoconstriction in the rat thyroid gland.

Animals

Training people with HIV disease for involvement in community planning process: Project LEAP. Learning Empowerment Advocacy, Participation.

Social and political pressure, as well as public health theory, mandate inclusion of PLWHIV in community planning and policy development processes. Barriers to PLWHIV participation may be cognitive, instrumental, and/or affective. The authors report on development, implementation, and initial evaluation of a pilot project testing a psychoeducational intervention to increase organizational participation by people with HIV. Organizational participation by individual increased from a mean of 0.5 organizations at entry to 2.3 at follow-up. Evaluation data indicate that increases in self-esteem, self-confidence, and specific knowledge, along with demystification of organizational operations, networking, and modeling by project staff contributed to the outcome.

Adult